A detailed history of Prospera Financial Services Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Prospera Financial Services Inc holds 73,255 shares of BMY stock, worth $4.23 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
73,255
Previous 52,339 39.96%
Holding current value
$4.23 Million
Previous $2.17 Million 74.41%
% of portfolio
0.1%
Previous 0.06%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$39.66 - $51.75 $829,528 - $1.08 Million
20,916 Added 39.96%
73,255 $3.79 Million
Q2 2024

Aug 13, 2024

BUY
$40.25 - $52.99 $973,043 - $1.28 Million
24,175 Added 85.84%
52,339 $2.17 Million
Q1 2024

Aug 13, 2024

SELL
$47.98 - $54.4 $560,982 - $636,044
-11,692 Reduced 22.34%
40,647 $2.2 Million
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $160,905 - $192,004
-3,319 Reduced 10.54%
28,164 $1.45 Million
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $237,349 - $265,393
4,100 Added 14.97%
31,483 $1.83 Million
Q2 2023

Aug 08, 2023

BUY
$63.71 - $70.74 $46,572 - $51,710
731 Added 2.74%
27,383 $1.75 Million
Q1 2023

May 12, 2023

SELL
$65.71 - $74.53 $10,710 - $12,148
-163 Reduced 0.61%
26,652 $1.85 Million
Q4 2022

Feb 08, 2023

SELL
$68.48 - $81.09 $31,500 - $37,301
-460 Reduced 1.69%
26,815 $1.93 Million
Q3 2022

Oct 27, 2022

BUY
$0.13 - $76.84 $149 - $88,135
1,147 Added 4.39%
27,275 $1.94 Million
Q2 2022

Aug 08, 2022

BUY
$72.62 - $79.98 $235,724 - $259,615
3,246 Added 14.19%
26,128 $2.01 Million
Q1 2022

May 04, 2022

BUY
$61.48 - $73.72 $22,255 - $26,686
362 Added 1.61%
22,882 $1.67 Million
Q4 2021

Feb 10, 2022

BUY
$53.63 - $62.52 $316,577 - $369,055
5,903 Added 35.52%
22,520 $1.41 Million
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $417,030 - $488,496
-7,048 Reduced 29.78%
16,617 $984,000
Q2 2021

Aug 12, 2021

BUY
$61.91 - $67.42 $296,177 - $322,537
4,784 Added 25.34%
23,665 $1.58 Million
Q1 2021

May 06, 2021

SELL
$59.34 - $66.74 $154,105 - $173,323
-2,597 Reduced 12.09%
18,881 $1.19 Million
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $501,471 - $568,259
8,685 Added 67.89%
21,478 $1.33 Million
Q3 2020

Nov 04, 2020

SELL
$57.43 - $63.64 $172,979 - $191,683
-3,012 Reduced 19.06%
12,793 $771,000
Q2 2020

Aug 07, 2020

BUY
$54.82 - $64.09 $20,667 - $24,161
377 Added 2.44%
15,805 $929,000
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $286,288 - $416,043
-6,170 Reduced 28.57%
15,428 $860,000
Q4 2019

Feb 12, 2020

BUY
$49.21 - $64.19 $492,493 - $642,413
10,008 Added 86.35%
21,598 $1.39 Million
Q3 2019

Oct 22, 2019

BUY
$42.77 - $50.71 $30,708 - $36,409
718 Added 6.6%
11,590 $588,000
Q2 2019

Aug 14, 2019

BUY
$44.62 - $49.34 $1.79 Million - $1.98 Million
40,057 New
40,057 $2.06 Million
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $1.3 Million - $1.44 Million
-29,185 Reduced 72.86%
10,872 $495,000
Q1 2019

May 02, 2019

SELL
$45.12 - $53.8 $1.81 Million - $2.16 Million
-40,057 Closed
0 $0
Q4 2018

Feb 13, 2019

SELL
$48.76 - $63.23 $134,138 - $173,945
-2,751 Reduced 6.43%
40,057 $2.06 Million
Q3 2018

Oct 25, 2018

SELL
$55.19 - $62.25 $348,855 - $393,482
-6,321 Reduced 12.87%
42,808 $2.58 Million
Q2 2018

Jul 18, 2018

SELL
$50.53 - $62.98 $1,768 - $2,204
-35 Reduced 0.07%
49,129 $2.73 Million
Q1 2018

Apr 12, 2018

SELL
$59.92 - $68.98 $131,584 - $151,480
-2,196 Reduced 4.28%
49,164 $3.1 Million
Q4 2017

Jan 24, 2018

SELL
$59.94 - $65.35 $777,182 - $847,328
-12,966 Reduced 20.16%
51,360 $3.16 Million
Q3 2017

Oct 11, 2017

BUY
$55.23 - $63.74 $3.55 Million - $4.1 Million
64,326
64,326 $4.14 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Prospera Financial Services Inc Portfolio

Follow Prospera Financial Services Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prospera Financial Services Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prospera Financial Services Inc with notifications on news.